[go: up one dir, main page]

LT3302471T - Tetrapakeistieji alkenų junginiai ir jų panaudojimas - Google Patents

Tetrapakeistieji alkenų junginiai ir jų panaudojimas

Info

Publication number
LT3302471T
LT3302471T LTEPPCT/US2016/034782T LT16034782T LT3302471T LT 3302471 T LT3302471 T LT 3302471T LT 16034782 T LT16034782 T LT 16034782T LT 3302471 T LT3302471 T LT 3302471T
Authority
LT
Lithuania
Prior art keywords
alkene compounds
tetrasubstituted alkene
tetrasubstituted
compounds
alkene
Prior art date
Application number
LTEPPCT/US2016/034782T
Other languages
English (en)
Inventor
Mark Bock
Ming-Hong Hao
Manav KORPAL
Vijay Kumar Nyavanandi
Xiaoling Puyang
Susanta Samajdar
Peter Gerard Smith
John Wang
Guo Zhu Zheng
Ping Zhu
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of LT3302471T publication Critical patent/LT3302471T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/US2016/034782T 2015-05-29 2016-05-27 Tetrapakeistieji alkenų junginiai ir jų panaudojimas LT3302471T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562168581P 2015-05-29 2015-05-29
US201562168529P 2015-05-29 2015-05-29
US201562269745P 2015-12-18 2015-12-18
PCT/US2016/034782 WO2016196346A1 (en) 2015-05-29 2016-05-27 Tetrasubstituted alkene compounds and their use

Publications (1)

Publication Number Publication Date
LT3302471T true LT3302471T (lt) 2021-10-11

Family

ID=57398096

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/034782T LT3302471T (lt) 2015-05-29 2016-05-27 Tetrapakeistieji alkenų junginiai ir jų panaudojimas

Country Status (34)

Country Link
US (2) US9796683B2 (lt)
EP (2) EP3302471B1 (lt)
JP (1) JP6325760B1 (lt)
KR (1) KR102664618B1 (lt)
CN (2) CN113024466A (lt)
AU (1) AU2016271126B2 (lt)
BR (1) BR112017025546B1 (lt)
CA (1) CA2987321C (lt)
CL (1) CL2017002996A1 (lt)
CO (1) CO2017013432A2 (lt)
CY (1) CY1125068T1 (lt)
DK (1) DK3302471T3 (lt)
ES (1) ES2895511T3 (lt)
HR (1) HRP20211542T1 (lt)
HU (1) HUE056199T2 (lt)
IL (1) IL255765B2 (lt)
JO (1) JO3735B1 (lt)
LT (1) LT3302471T (lt)
MA (1) MA43364B1 (lt)
MD (1) MD3302471T2 (lt)
MX (1) MX379297B (lt)
MY (1) MY186977A (lt)
PE (1) PE20181083A1 (lt)
PH (1) PH12017502142B1 (lt)
PL (1) PL3302471T3 (lt)
PT (1) PT3302471T (lt)
RS (1) RS62481B1 (lt)
RU (1) RU2733741C2 (lt)
SI (1) SI3302471T1 (lt)
SM (1) SMT202100599T1 (lt)
TW (1) TWI704137B (lt)
UA (1) UA120882C2 (lt)
WO (2) WO2016196346A1 (lt)
ZA (1) ZA201707912B (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987321C (en) 2015-05-29 2023-09-19 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
CN110267940A (zh) * 2016-11-24 2019-09-20 卫材 R&D 管理有限公司 四取代的烯烃化合物和它们的用途
US20200255415A1 (en) * 2016-11-24 2020-08-13 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use for the treatment of breast cancer
WO2018097273A1 (en) * 2016-11-28 2018-05-31 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
SG11201908531WA (en) * 2017-03-16 2019-10-30 Eisai R&D Man Co Ltd Combination therapies for the treatment of breast cancer
WO2019225552A1 (en) * 2018-05-22 2019-11-28 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
CA3122621A1 (en) 2018-12-17 2020-06-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Estrogen receptor antagonist
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2021014349A (es) 2019-05-24 2022-01-06 Eisai R&D Man Co Ltd Metodo para tratar cancer con una forma de dosificacion oral de un inhibidor de receptores de estrogeno-alfa.
CN113874367B (zh) 2019-06-19 2024-09-13 江苏恒瑞医药股份有限公司 吲唑类衍生物、其制备方法及其在医药上的应用
CN110452177A (zh) * 2019-09-02 2019-11-15 南通大学 一种5-溴-4-氟-1h-吲唑的合成方法
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022001971A1 (zh) 2020-06-28 2022-01-06 南京明德新药研发有限公司 并环吲唑类化合物
CA3199087A1 (en) 2020-11-06 2022-05-12 Eisai R&D Management Co., Ltd. Method of treating breast cancer
TW202241879A (zh) * 2020-12-18 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
CN114644616B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
CN114644615B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的结晶形式及其制备方法
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN117440950A (zh) * 2021-06-27 2024-01-23 北京盛诺基医药科技股份有限公司 一种ERα受体共价结合拮抗剂
CN115960082B (zh) * 2021-10-13 2024-06-07 长春金赛药业有限责任公司 一种四取代的烯烃化合物、其制备方法及其在医药上的应用
CN117550980A (zh) * 2023-12-04 2024-02-13 宁夏瑞泰科技股份有限公司 一种制备n-乙基-1,6-己二胺的方法和由其制得的产品

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (de) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand Steroidhormonrezeptoraffine antitumorwirkstoffe
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US8063249B1 (en) * 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
WO2011046596A2 (en) 2009-10-13 2011-04-21 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
WO2011129837A1 (en) 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
CA2866891A1 (en) 2012-03-20 2013-09-26 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20150258080A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic combinations with estrogen receptor modulators
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
CA2987321C (en) 2015-05-29 2023-09-19 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Also Published As

Publication number Publication date
CA2987321A1 (en) 2016-12-08
MD3302471T2 (ro) 2021-12-31
UA120882C2 (uk) 2020-02-25
MX2017015226A (es) 2018-02-19
MX379297B (es) 2025-03-10
BR112017025546B1 (pt) 2023-02-14
EP3302471A4 (en) 2018-10-10
US20160347717A1 (en) 2016-12-01
AU2016271126B2 (en) 2020-09-24
BR112017025546A2 (pt) 2018-08-07
HUE056199T2 (hu) 2022-01-28
ZA201707912B (en) 2019-05-29
PL3302471T3 (pl) 2022-02-07
IL255765B1 (en) 2023-06-01
RS62481B1 (sr) 2021-11-30
PH12017502142A1 (en) 2018-06-11
DK3302471T3 (da) 2021-11-15
RU2733741C2 (ru) 2020-10-06
ES2895511T3 (es) 2022-02-21
NZ737512A (en) 2024-09-27
JP6325760B1 (ja) 2018-05-16
US10851065B2 (en) 2020-12-01
CA2987321C (en) 2023-09-19
RU2017146408A (ru) 2019-07-02
JO3735B1 (ar) 2021-01-31
JP2018516250A (ja) 2018-06-21
PE20181083A1 (es) 2018-07-05
IL255765A (en) 2018-01-31
TW201706250A (zh) 2017-02-16
PH12017502142B1 (en) 2024-07-03
WO2016196337A1 (en) 2016-12-08
MA43364B1 (fr) 2021-11-30
US9796683B2 (en) 2017-10-24
IL255765B2 (en) 2023-10-01
CY1125068T1 (el) 2023-03-24
EP3302471B1 (en) 2021-08-25
KR20180011274A (ko) 2018-01-31
TWI704137B (zh) 2020-09-11
EP3981766A1 (en) 2022-04-13
CL2017002996A1 (es) 2018-03-23
MA43364A (fr) 2021-04-14
WO2016196346A1 (en) 2016-12-08
US20180127378A1 (en) 2018-05-10
CN107847498A (zh) 2018-03-27
SI3302471T1 (sl) 2021-11-30
HRP20211542T1 (hr) 2022-01-07
PT3302471T (pt) 2021-11-02
KR102664618B1 (ko) 2024-05-10
EP3302471A1 (en) 2018-04-11
CN113024466A (zh) 2021-06-25
CO2017013432A2 (es) 2018-05-21
SMT202100599T1 (it) 2021-11-12
RU2017146408A3 (lt) 2019-10-18
MY186977A (en) 2021-08-26
CN107847498B (zh) 2021-04-13
AU2016271126A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
ZA201707912B (en) Tetrasubstituted alkene compounds and their use
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
PL3215147T3 (pl) Związki norketaminy osłabiającej działanie układu nerwowego i sposoby
SG11201706029VA (en) Anti-senescence compounds and uses thereof
ZA201705456B (en) Benzoxaborole compounds and uses thereof
IL251107A0 (en) Compounds and methods
GB201507753D0 (en) New compounds and uses
GB201504763D0 (en) Compounds and uses
IL253459B (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
HK1248143A1 (en) Tetrasubstituted alkene compounds and their use
GB2543375B (en) Compounds and their uses
GB201614874D0 (en) New compounds and uses
GB201514770D0 (en) Compounds and their use
GB201507752D0 (en) New compounds and uses
GB201513318D0 (en) Novel compounds and their use
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201402467D0 (en) New Compounds and uses
GB201404301D0 (en) Compounds and combinations
GB201413411D0 (en) Novel compounds and their use
GB201404438D0 (en) Polyamine compounds and uses thereof